Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
1 competitor in HER2+ Breast Cancer
View Full LandscapeTarget Indication
HER2+ Breast Cancer
Mechanism of Action
HER2 Kinase Inhibitor
Clinical Trial
NCT02614794Last updated: 12/3/2025
Latest Patent Expiry
Patents Listed
7
Exclusivity
Application
NDA 213411Tukysa
Tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2?positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-HER2 treatment regimens.
View on EMA